Genenta Science (NASDAQ:GNTA) Shares Down 1.3% – Here’s Why

Genenta Science S.p.A. (NASDAQ:GNTA)’s share price was down 1.3% during trading on Friday . The stock traded as low as $3.51 and last traded at $3.76. Approximately 22,483 shares changed hands during mid-day trading, an increase of 43% from the average daily volume of 15,753 shares. The stock had previously closed at $3.81.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Genenta Science in a research report on Wednesday, October 2nd.

Genenta Science Price Performance

The company’s 50-day moving average is $4.88 and its 200 day moving average is $4.55.

Hedge Funds Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new position in Genenta Science S.p.A. (NASDAQ:GNTA) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science at the end of the most recent quarter. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.